Published in Expert Rev Vaccines on January 13, 2016
Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis | NCT01154049
Discovery of Antischistosomal Drug Leads Based on Tetraazamacrocyclic Derivatives and Their Metal Complexes. Antimicrob Agents Chemother (2016) 0.75
Sm-p80-Based Schistosomiasis Vaccine: Preparation for Human Clinical Trials. Trends Parasitol (2016) 0.75
Cross-species prophylactic efficacy of Sm-p80-based vaccine and intracellular localization of Sm-p80/Sm-p80 ortholog proteins during development in Schistosoma mansoni, Schistosoma japonicum, and Schistosoma haematobium. Parasitol Res (2017) 0.75
Control of neglected tropical diseases. N Engl J Med (2007) 14.49
Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis (2006) 13.74
Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop (2003) 6.64
The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases. PLoS Negl Trop Dis (2014) 4.01
Schistosomiasis elimination: lessons from the past guide the future. Lancet Infect Dis (2010) 3.63
Current status of vaccines for schistosomiasis. Clin Microbiol Rev (2008) 3.47
Parasites and poverty: the case of schistosomiasis. Acta Trop (2009) 3.18
Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis. Nat Med (2006) 2.59
Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One (2011) 2.39
The epidemiology of schistosomiasis in Egypt: summary findings in nine governorates. Am J Trop Med Hyg (2000) 1.77
Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines (2011) 1.75
A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One (2010) 1.57
Schistosomiasis reaches Europe. Lancet Infect Dis (2015) 1.50
Schistosomiasis control: praziquantel forever? Mol Biochem Parasitol (2014) 1.40
Schistosomiasis haematobium, Corsica, France. Emerg Infect Dis (2014) 1.39
Immunity induced by the radiation-attenuated schistosome vaccine. Parasite Immunol (2005) 1.37
Schistosomes: the road from host-parasite interactions to vaccines in clinical trials. Trends Parasitol (2005) 1.36
Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis. J Control Release (2013) 1.25
A Schistosoma mansoni fatty acid-binding protein, Sm14, is the potential basis of a dual-purpose anti-helminth vaccine. Proc Natl Acad Sci U S A (1996) 1.25
Schistosomiasis vaccines. Hum Vaccin (2011) 1.23
Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. PLoS One (2012) 1.22
Natural versus drug-induced resistance in Schistosoma mansoni infection. Parasitol Today (2000) 1.17
Characterization of Ca(2+)-dependent neutral protease (calpain) from human blood flukes, Schistosoma mansoni. Biochim Biophys Acta (1993) 1.15
Vaccination with calpain induces a Th1-biased protective immune response against Schistosoma japonicum. Infect Immun (2001) 1.09
Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis. PLoS Negl Trop Dis (2012) 1.08
Elimination of Schistosoma mansoni Adult Worms by Rhesus Macaques: Basis for a Therapeutic Vaccine? PLoS Negl Trop Dis (2008) 1.08
Sm-p80-based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni. Parasite Immunol (2009) 1.06
Protective and antifecundity effects of Sm-p80-based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model. Vaccine (2009) 1.04
Adjuvants for malaria vaccines. Parasite Immunol (2009) 1.04
Enhanced protective efficacy of a chimeric form of the schistosomiasis vaccine antigen Sm-TSP-2. PLoS Negl Trop Dis (2012) 1.01
Multiple introductions of highly pathogenic avian influenza H5N1 viruses into Bangladesh. Emerg Microbes Infect (2014) 1.01
The protective effect of a Schistosoma japonicum Chinese strain 23 kDa plasmid DNA vaccine in pigs is enhanced with IL-12. Vaccine (2004) 1.00
Pilot field trial of the EG95 vaccine against ovine cystic echinococcosis in Rio Negro, Argentina: early impact and preliminary data. Acta Trop (2013) 1.00
Prime-boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by the irradiated cercarial vaccine. Parasitol Res (2009) 1.00
The biotechnology-value chain: development of Sm14 as a schistosomiasis vaccine. Acta Trop (2008) 1.00
Sm-p80-based DNA vaccine provides baboons with levels of protection against Schistosoma mansoni infection comparable to those achieved by the irradiated cercarial vaccine. J Infect Dis (2010) 0.99
Immunology of human schistosomiasis. Parasite Immunol (2014) 0.99
Research on calpain of Schistosoma japonicum as a vaccine candidate. Parasitol Int (2004) 0.98
Role of adjuvants in modeling the immune response. Curr Opin HIV AIDS (2010) 0.96
Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-γ. Eur J Immunol (2014) 0.96
Epidemiology of Schistosomiasis in Egypt: Travel through Time: Review. J Adv Res (2012) 0.95
Proteomics at the schistosome-mammalian host interface: any prospects for diagnostics or vaccines? Parasitology (2012) 0.95
Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimen. PLoS One (2014) 0.94
Vaccine potential of a recombinant glutathione S-transferase cloned from Schistosoma haematobium in primates experimentally infected with an homologous challenge. Vaccine (1999) 0.94
Cellular and humoral immune responses and protection against schistosomes induced by a radiation-attenuated vaccine in chimpanzees. Infect Immun (2001) 0.94
An immunomics approach to schistosome antigen discovery: antibody signatures of naturally resistant and chronically infected individuals from endemic areas. PLoS Pathog (2014) 0.93
Current status and future prospects for a vaccine against schistosomiasis. Expert Rev Vaccines (2004) 0.92
A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine (2011) 0.91
Sm-p80-based DNA vaccine made in a human use approved vector VR1020 protects against challenge infection with Schistosoma mansoni in mouse. Parasite Immunol (2010) 0.90
Schistosomiasis elimination strategies and potential role of a vaccine in achieving global health goals. Am J Trop Med Hyg (2014) 0.90
Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice. Int J Infect Dis (2010) 0.89
Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females. ISRN Obstet Gynecol (2011) 0.89
Landmark green light for Mosquirix malaria vaccine. Nat Biotechnol (2015) 0.88
Use of an Sm-p80-based therapeutic vaccine to kill established adult schistosome parasites in chronically infected baboons. J Infect Dis (2014) 0.87
Schistosoma japonicum triose-phosphate isomerase plasmid DNA vaccine protects pigs against challenge infection. Parasitology (2006) 0.87
Cross-species protection: Schistosoma mansoni Sm-p80 vaccine confers protection against Schistosoma haematobium in hamsters and baboons. Vaccine (2014) 0.87
Prospects for a schistosome vaccine. Curr Drug Targets Immune Endocr Metabol Disord (2002) 0.87
Successful immunization of naturally reared pigs against porcine cysticercosis with a recombinant oncosphere antigen vaccine. Vet Parasitol (2012) 0.86
Schistosoma mansoni antigen Sm-p80: Prophylactic efficacy of a vaccine formulated in human approved plasmid vector and adjuvant (VR 1020 and alum). Acta Trop (2011) 0.86
Virulence factors of schistosomes. Microbes Infect (2012) 0.86
Elimination of a primary schistosome infection from rats coincides with elevated IgE titres and mast cell degranulation. Parasite Immunol (1997) 0.86
Construction and evaluation of replication-defective recombinant optimized triosephosphate isomerase adenoviral vaccination in Schistosoma japonicum challenged mice. Vaccine (2014) 0.85
Development of the Brazilian Anti Schistosomiasis Vaccine Based on the Recombinant Fatty Acid Binding Protein Sm14 Plus GLA-SE Adjuvant. Front Immunol (2015) 0.85
Induction of protective immune responses against schistosomiasis using functionally active cysteine peptidases. Front Genet (2014) 0.84
Longevity of Sm-p80-specific antibody responses following vaccination with Sm-p80 vaccine in mice and baboons and transplacental transfer of Sm-p80-specific antibodies in a baboon. Parasitol Res (2014) 0.84
A multivalent chimeric vaccine composed of Schistosoma mansoni SmTSP-2 and Sm29 was able to induce protection against infection in mice. Parasite Immunol (2014) 0.84
Something old, something new: is praziquantel enough for schistosomiasis control? Future Med Chem (2015) 0.84
Induction of Protective Immune Responses Against Schistosomiasis haematobium in Hamsters and Mice Using Cysteine Peptidase-Based Vaccine. Front Immunol (2015) 0.83
Role of antibody dependent cell mediated cytotoxicity (ADCC) in Sm-p80-mediated protection against Schistosoma mansoni. Vaccine (2012) 0.83
A multi-component integrated approach for the elimination of schistosomiasis in the People's Republic of China: design and baseline results of a 4-year cluster-randomised intervention trial. Int J Parasitol (2014) 0.83
Schistosomiasis vaccine candidate Sm14/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults. Vaccine (2015) 0.83
Development of Paramyosin as a Vaccine Candidate for Schistosomiasis. Front Immunol (2015) 0.82
Glutathione S-transferases of 28kDa as major vaccine candidates against schistosomiasis. Mem Inst Oswaldo Cruz (1998) 0.82
Vaccination with antioxidant enzymes confers protective immunity against challenge infection with Schistosoma mansoni. Mem Inst Oswaldo Cruz (2004) 0.81
Eliminating Schistosomes through Vaccination: What are the Best Immune Weapons? Front Immunol (2015) 0.81
Combination of the two schistosomal antigens Sm14 and Sm29 elicits significant protection against experimental Schistosoma mansoni infection. Exp Parasitol (2014) 0.80
A quantitative proteomic analysis of the tegumental proteins from Schistosoma mansoni schistosomula reveals novel potential therapeutic targets. Int J Parasitol (2015) 0.80
Vaccines and diagnostics for zoonotic schistosomiasis japonica. Parasitology (2014) 0.79
Fusion protein comprised of the two schistosomal antigens, Sm14 and Sm29, provides significant protection against Schistosoma mansoni in murine infection model. BMC Infect Dis (2015) 0.78
Editorial: The Schistosomiasis Vaccine - It is Time to Stand up. Front Immunol (2015) 0.77
Immuno-evasive tactics by schistosomes identify an effective allergy preventative. Exp Parasitol (2015) 0.77
Hepatitis B Vaccines and HPV Vaccines Have Been Hailed as Major Public Health Achievements in Preventing Cancer--Could a Schistosomiasis Vaccine be the Third? PLoS Negl Trop Dis (2015) 0.77
Simultaneous priming with DNA encoding Sm-p80 and boosting with Sm-p80 protein confers protection against challenge infection with Schistosoma mansoni in mice. Parasitol Res (2014) 0.76